The Delhi High court on 4 March issued a notice against the COVID-19 Vaccine manufacturers. It alleges non-utilization of the vaccines to their full capacity and noted that there has to be a “sense of urgency.” The leading producers, Bharat Biotech and Serum Institute of India (SII) to disclose their capacity of manufacturing the Covaxin and Covishield vaccine.
The DHC views
The bench of Justice Vipin Sanghi and Rekha Palli said, “We are not utilizing Covid-19 vaccines fully. We are either donating it to foreign countries or selling it to them and are not vaccinating our own people. So there has to be that sense of responsibility and urgency.”
As per the court, the Union of India shall explain the rationale behind strict control over the class of persons who can be vaccinated under the last phase. The Delhi High Court Bar Association and Bar Council of Delhi are ordered to file an affidavit disclosing the judicial strength.
Orders to the manufacturers
Bharat Biotech and Serum Institute of India are commanded to file separate affidavits on their capacity to manufacture the vaccines per day/week/month basis and also the current optic of the vaccines and the unused capacity.
TPT Policy Advocacy & Recommendations
- The Indian Judiciary should focus on resolving the logistic problems, pending cases and delivering sermons rather than stepping out of their domain and interfering in the administration.
- However, with recent coalitions, it is quite evident that the nation is thriving to generate resources rather than focusing on the inoculation of its citizens. Several rural areas of the country are still deprived of the jabs, which contributes majorly to the resurgence. The Indian government should follow the constitution ‘Of the people, for the people and by the people’ as they form the foundation of vision ‘Atmanirbhar Bharat’.